Management of Diabetic Macular Edema using Intravitreal Bevacizumab versus Intravitreal Triamcinolone: Systematic Review and Meta-Analysis

被引:0
作者
Aljarabah, Enas Ali [1 ]
Babaker, Raghad Khalid [2 ]
Alqawili, Alanoud Abdullah [3 ]
Almalki, Mohammed Ahmed [4 ]
Alghamdi, Abdullah Salem [4 ]
Almuafa, Majed Abdullah [5 ]
Alsubaie, Nawaf Ammash [6 ]
Alghamdi, Thekra Ali [7 ]
机构
[1] Secur Forces Hosp, Dept Opthalmol, Dammam, Saudi Arabia
[2] King Abdulaziz Univ, Dept Med, Jeddah, Saudi Arabia
[3] Almaerfa Coll, Dept Med, Riyadh, Saudi Arabia
[4] King Fahad Hosp, Dept Med, Mecca, Saudi Arabia
[5] King Fahad Hosp, Dept Med, Albaha, Saudi Arabia
[6] Prince Saud Bin Jalawy Hosp, Dept Med, Alahsa, Saudi Arabia
[7] Maternal & Childrens Hosp, Dept Med, Jeddah, Saudi Arabia
关键词
Diabetic macular edema; Intravitreal bevacizumab; Intravitreal triamcinolone; RISK-FACTORS; ACETONIDE; PREVALENCE; INJECTIONS; THERAPY;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background and aim: Triamcinolone, as an ocular steroid, plays an anti-inflammatory, anti-angiogenic, and cost-effective role in the treatment of DME. Meanwhile, the humanized monoclonal antibody bevacizumab shows promising anti-VEGF results when used as an off-label therapeutic option because it is less expensive than most anti-VEGF agents. This work aims to determine the efficacy and safety of Intravitreal Bevacizumab (IVB), versus Intravitreal Triamcinolone (IVT) in Diabetic Macular Edema (DME) patients. Methodology: A systematic search was performed over different medical databases to identify ophthalmology studies, which studied the outcome of the IVB group versus the IVT group of DME patients. We conducted a meta-analysis process on Best-Corrected Visual Acuity (BCVA) and Central Macular Thickness (CMT), as primary outcomes, and on Intraocular Pressure (IOP) as a secondary outcome. Eight studies were identified involving 564 eyes, 285 in the IVB group, and 279 in the IVT group. Our meta-analysis process showed a highly significant decrease in mean CMT in the IVB group compared to the IVT group (p=0.043). But, there was a non-significant difference in mean BCVA and IOP between groups (p>0.05) respectively. Conclusion: To conclude, this study compares the efficacy and safety of Intravitreal Bevacizumab (IVB), versus Intravitreal Triamcinolone (IVT) in Diabetic Macular Edema, according to our results IVB was more effective than IVT in CRT reduction but no difference between both in best-corrected visual acuity and on Intraocular Pressure (IOP) parameters.
引用
收藏
页码:32 / 37
页数:6
相关论文
共 50 条
[21]   Effect of Intravitreal Bevacizumab with or without Macular Photocoagulation for Diabetic Macular Edema: A Meta-Analysis [J].
Kang Xiao ;
Shi-Jia Weng ;
Shen-Zhi Liang ;
Jiong Wang ;
Cheng Qian ;
Guang-Ming Wan .
Diabetes Therapy, 2018, 9 :2369-2381
[22]   Comparison of intravitreal bevacizumab with macular photocoagulation for treatment of diabetic macular edema: a systemic review and Meta-analysis [J].
Liu, Xiang-Dong ;
Zhou, Xiao-Dong ;
Wang, Zhi ;
Shen, Hong-Jie .
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2014, 7 (06) :1048-1055
[23]   Intravitreal Bevacizumab Alone Vs Combined With Topical Timolol-Dorzolamide or Dorzolamide for Diabetic Macular Edema: A Systematic Review and Meta-Analysis [J].
Hubayni, Rahaf A. ;
Qedair, Jumanah ;
Bukhari, Ziad M. ;
Alsudais, Ali S. ;
Badghaish, Orjwan Salah ;
Bawazir, Razan Osama ;
Alqahtani, Abdullah S. ;
Almarzouki, Hashem .
CLINICAL OPHTHALMOLOGY, 2025, 19 :1007-1019
[24]   Intravitreal Triamcinolone for the Treatment of Diabetic Macular Edema [J].
Gomez-Ulla, Francisco ;
Marticorena, Joaquin ;
Alfaro, D. Virgil, III ;
Fernandez, Maribel ;
Mendez, Elizabeth Rodriguez ;
Rothen, Michelle .
CURRENT DIABETES REVIEWS, 2006, 2 (01) :99-112
[25]   Combined Intravitreal Bevacizumab and Triamcinolone Injection for Refractory Diabetic Macular Edema [J].
Bardak, Yavuz ;
Bardak, Hatun Handan ;
Ekim, Mustafa Muhterem .
OPHTHALMOLOGICA, 2014, 232 :16-16
[26]   Comparison of Grid Laser, Intravitreal Triamcinolone, and Intravitreal Bevacizumab in the Treatment of Diffuse Diabetic Macular Edema [J].
Sobaci, Gungor ;
Ozge, Gokhan ;
Erdurman, Cuneyt ;
Durukan, Hakan A. ;
Bayraktar, Zeki M. .
OPHTHALMOLOGICA, 2012, 227 (02) :95-99
[27]   Intravitreal triamcinolone acetonide for diabetic macular edema and macular edema secondary to retinal vein occlusion: a meta-analysis [J].
Mihalache, Andrew ;
Hatamnejad, Amin ;
Patil, Nikhil S. ;
Popovic, Marko M. ;
Kertes, Peter J. ;
Cruz-Pimentel, Miguel ;
Muni, Rajeev H. .
OPHTHALMOLOGICA, 2024, 247 (01) :19-29
[28]   Comparison of intravitreal bevacizumab and triamcinolone acetonide theraphies for diffuse diabetic macular edema [J].
Aksoy, Sibel ;
Yilmaz, Gursel ;
Akkoyun, Imren ;
Yazici, Ayse Canan .
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2015, 8 (03) :550-555
[29]   Factors influencing intravitreal bevacizumab and triamcinolone treatment in patients with diabetic macular edema [J].
Kim, Tai K. ;
Shin, Hye Y. ;
Kim, Su Y. ;
Lee, Young C. ;
Lee, Mee Y. .
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2017, 27 (06) :746-750
[30]   Comparison of intravitreal bevacizumab and triamcinolone acetonide theraphies for diffuse diabetic macular edema [J].
Sibel Aksoy ;
Gursel Yilmaz ;
Imren Akkoyun ;
Ayse Canan Yazici .
International Journal of Ophthalmology, 2015, (03) :550-555